Study evaluates myeloma treatment combination | Review compares hepatitis C regimens | Researchers discover protein related to rapid malaria growth
November 17, 2015
AABB SmartBrief
News for the transfusion medicine and cellular therapy community

Top StorySponsored By
Study evaluates myeloma treatment combination
A 73-patient, Phase Ib/II trial found that the combination of elotuzumab, lenalidomide and dexamethasone yielded an 84% objective response rate among treatment-experienced patients with relapsed multiple myeloma. The patients had not been treated with lenalidomide. The findings were reported in the journal The Lancet Haematology, and additional trials using the drug combination to treat multiple myeloma are underway. (11/16)
Share: LinkedInTwitterFacebookGoogle+Email
Immucor - We Know Blood Banking
How does Immucor provide the highest level of support? The majority of our customer-facing team has previously worked in the blood bank laboratory. Their knowledge of your day to day operations comes from their direct experience. Click here to learn more about how Immucor can improve your lab's operations.
Science & HealthSponsored By
Review compares hepatitis C regimens
A systematic review of three clinical trials found that the combination of hepatitis C drugs daclatasvir and sofosbuvir was associated with higher rates of sustained virologic response among patients with both HIV and hepatitis C compared with sofosbuvir and ribavirin. The rates of treatment discontinuation due to adverse events were lower in the daclatasvir-sofosbuvir cohort. The findings were presented at the Liver Meeting. (11/15)
Share: LinkedInTwitterFacebookGoogle+Email
5 Keys to Launching a Killer Website
Because websites serve many functions and have moving parts, it's a serious undertaking to design, build and launch a site. If you want killer results, you need a solid plan. This eBook details five steps to launching a killer website.

Emerging Trends
Researchers discover protein related to rapid malaria growth
Scientists found that the cyclin protein plays a key role in the rapid cell division of the malaria parasite, allowing the parasites to infect red blood cells quickly. The study in the journal PLOS Pathogens identified three types of cyclin protein and found that the removal of CYC3 caused several abnormalities in the development of malaria parasites. Medical News Today (11/16), International Business Times (11/14)
Share: LinkedInTwitterFacebookGoogle+Email
Industry News & Practice
Leukemia trial of idelalisib is unblinded
An independent monitoring committee has unblinded a Phase III trial of Gilead's idelalisib with rituximab and bendamustine as a treatment for chronic lymphocytic leukemia after determining that the three-drug regimen delayed disease progression. Gilead intends to file regulatory applications in the US and Europe in 2016. Reuters (11/16)
Share: LinkedInTwitterFacebookGoogle+Email
Government & RegulatorySponsored By
Multiple myeloma drug from J&J receives FDA approval
Johnson & Johnson has won FDA approval for the use of Darzalex, or daratumumab, in multiple myeloma patients who have received at least three lines of standard therapies. The decision was backed by data from two trials, including a 42-patient study showing that tumors were completely or partially reduced in 36% of patients who took the drug. Reuters (11/16)
Share: LinkedInTwitterFacebookGoogle+Email
FDA approves 2 generic drugs from Mylan
Two generic drugs from Mylan will be introduced in the market after receiving clearance from the FDA. Mylan's generic version of Glucotrol XL, or glipizide extended-release tablets, is intended for use in type 2 diabetes patients, while its nevirapine extended-release tablets, a generic version of Viramune XR, were approved for the treatment of HIV-1 patients at least 6 years old in combination with other antiretroviral therapies. Drug Store News (11/16)
Share: LinkedInTwitterFacebookGoogle+Email
Limited Time Offer On AABB PBM Learning Modules
Designed to educate clinicians about all aspects of patient blood management (PBM) and ways to improve patient outcomes, the eight learning modules cover a range of critical topics such as PBM basics, building a program and intraoperative blood conservation. Purchase by Dec 31 to take advantage of the reduced prices.
Association News
AABB seeks nominations for 2016, 2017 Memorial Awards
AABB is seeking nominations for its 2016 and 2017 Memorial Awards, which will honor individuals who have advanced the practice of transfusion medicine, cellular therapies and patient blood management. The awards are presented to recognize achievements in administration, immunohematology, quality and innovative research, and overall outstanding service. Individuals are encouraged to nominate candidates by completing and submitting the online nomination form and supporting documentation by Friday, Jan. 29, 2016. Awards will be presented during the 2016 AABB Annual Meeting -- to be held Oct. 22-25 in Orlando, Fla. -- or during the 2017 AABB Annual Meeting in San Diego, Calif.
Share: LinkedInTwitterFacebookGoogle+Email
powered by
Director of Technical Services
Deployment Manager
Medical Technologist - $7500 Commitment Bonus
Associate Medical Director of Clinical Pathology Services
INOVA - Falls Church, VA
Silence is the bluntest of blunt instruments."
-- Erica Jong,
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AABB® ->Homepage | Join AABB | Conferences | Marketplace | AABB CareerLink
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Advertising:  Meryl Harold
  P: 202.407.7828
Editor:  Tom Parks

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information